Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer ( NEJ056 )
Cancer Science · 2024
DOI: 10.1111/cas.16340 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Science, 2024. Verfasst von Megumi Furuta und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Lung Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca K.K..
Abstract (Originalsprache)
Locoregional recurrence of non–small‐cell lung cancer (NSCLC) after complete resection lacks standard treatment. Durvalumab after chemoradiotherapy (CRT) or CRT alone is often selected in daily clinical practice for patients with locoregional recurrence; however, the therapeutic efficacy of these treatments remains unclear, and we aimed to assess this. This retrospective observational study used data from patients with NSCLC diagnosed with locoregional recurrence after complete resection who subsequently underwent concurrent CRT followed by durvalumab (CRT‐D group) or CRT alone (CRT group). We employed propensity score analysis with inverse probability treatment weighting (IPTW) to adjust for various confounders and evaluate efficacy in the CRT‐D group. After IPTW adjustment, the CRT‐D group contained 119 patients (64.7% male; 69.7% adenocarcinoma), and the CRT group contained 111 patients (60.5% male; 73.4% adenocarcinoma). Their mean ages were 66 and 65 years, respectively. The IPTW‐adjusted median progression‐free survival was 25.4 and 11.5 months for the CRT‐D and CRT groups, respectively (hazard ratio, 0.44; 95% confidence interval, 0.30–0.64); the median overall survival was not reached in either group favoring CRT‐D (hazard ratio, 0.49; 95% confidence interval, 0.24–0.99). Grade 3 or 4 adverse events were observed in 48.8% of patients during CRT, 10.7% after initiating durvalumab maintenance therapy in the CRT‐D group, and 57.3% in the CRT group. Overall, the sequential approach of CRT followed by durvalumab is a promising treatment strategy for locoregional recurrence of NSCLC after complete resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Megumi Furuta, Hidehito Horinouchi, Yusuke Uchinami
Förderung
- AstraZeneca K.K.
Zitieren
APA
Furuta, M., Horinouchi, H., Yokota, I., Yamaguchi, T., Itoh, S., Fukui, T., Iwashima, A., Sugisaka, J., Miura, Y., Tanaka, H., Miyawaki, T., Yokouchi, H., Miura, K., Saito, R., Saito, G., Kamoshida, T., Uchinami, Y., Kato, T., Kobayashi, K., & Asahina, H. (2024). Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer ( NEJ056 ). Cancer Science. https://doi.org/10.1111/cas.16340
Vancouver
Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, et al. Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer ( NEJ056 ). Cancer Science. 2024. doi:10.1111/cas.16340
BibTeX
@article{Furuta2024,
author = {Furuta, Megumi and Horinouchi, Hidehito and Yokota, Isao and Yamaguchi, Teppei and Itoh, Shoichi and Fukui, Takafumi and Iwashima, Akira and Sugisaka, Jun and Miura, Yu and Tanaka, Hisashi and Miyawaki, Taichi and Yokouchi, Hiroshi and Miura, Keita and Saito, Ryota and Saito, Go and Kamoshida, Tatsuhiko and Uchinami, Yusuke and Kato, Tatsuya and Kobayashi, Kunihiko and Asahina, Hajime},
title = {Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer ( NEJ056 )},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16340}
}
EUVIMED